Based on the diagnostic criteria
developed in 1999 by the World Health Organization, China has the largest
prevalent population of type 2 diabetes in the world. Combined with increasing
access to medical care and a burgeoning middle class that has newly acquired
economic clout, this large prevalent population promises double-digit pharmaceutical
sales growth and significant opportunity for multinational pharmaceutical
companies as demand for Western-branded antidiabetic drugs continues to grow
Questions Answered in This Report:
The risk of developing type 2 diabetes is at an all-time high in
China as a result of the country’s aging population and the influence of
urbanization—adoption of Western foods and lifestyles
and increasing obesity. What was the prevalence of type 2 diabetes in China
in 2012 and what factors will drive its growth through the decade? What changes
are expected in diagnosis and drug-treatment rates in urban and rural regions
Like their counterparts in the Western countries, Chinese physicians
are mostly influenced by a type 2 drug’s efficacy and safety profiles. How
are Western-branded drugs expected to fare against their Western branded
competitors and Chinese generics over the forecast period? What are the factors
influencing physicians’ decision to prescribe DPP-IV inhibitors and GLP-1
receptor agonists in China? What are the factors limiting their prescribing?
Boasting strong annual double-digit growth, China’s type 2
diabetes therapy market is growing rapidly. Which agents, current and
emerging, will be the key players driving market growth over the forecast
period? Which drugs will dominate the market by 2017? What is the reimbursement
status of multinational brands today and in 2017?
Primary research: 90 physician surveys in Beijing,
Shanghai, and Guangzhou. Separate in-depth interviews with 8 medical experts.
Epidemiology: Prevalence of type 2 diabetes in urban
and rural China. Ten-year epidemiology forecast (2012-2022).
Market forecast features: Our analysis evaluates the
size of the patient population, percentage of diagnosed patients, and percentage
of drug-treated patients. We include a detailed forecast for antidiabetic drug
classes and leading products over 2012-2017 using a combination of historical
trend analysis and an epidemiology-based bottom-up market model.